![](https://investorshub.advfn.com/uicon/716135.png?cb=1646342716)
Tuesday, April 07, 2020 9:14:56 PM
RE: The OPTIMA Phase 3 study: We’ve also said that there is a higher probability of success at the second interim analysis, now anticipated by June of next year, just 7 or 8 short months from now. We stand by that guidance.
From the March 2020 Corp Presentation.
OPTIMA Study, a global Phase III trial in HCC/Primary Liver Cancer, with 2nd interim data expected in early 3rd Quarter of 2020
Hmmm, It appears that it is taking longer than first thought. That is a good thing, when people live longer in a trial that measures how long participants live...
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM